Jurkat-Dual™ Cells

Product Unit size Cat. code Docs. Qty. Price

Jurkat-Dual™ cells

Human T Lymphocytes - NF-κB/IRF reporter cells

Show product

3-7 x 10e6 cells


NF-κB and IRF signaling in Jurkat-Dual™ cells
NF-κB & IRF signaling in Jurkat-Dual™ cells

IRF-SEAP & NF-κB-Luc Reporter T Lymphocytes

Jurkat-Dual™ cells are engineered reporter T lymphocytes designed for the study of transcription factor activation in a physiologically-relevant cell line. These cells stably express two inducible reporter constructs; interferon regulatory factor-inducible secreted embryonic alkaline phosphatase (IRF-SEAP) and NF-κB-Lucia luciferase (NF-κB-Luc) reporter genes. They were derived from the human T lymphocyte-based Jurkat cell line.

 More details


Cell line description:

Jurkat-Dual™ cells feature the Lucia luciferase gene, a secreted luciferase reporter gene, driven by an interferon-β (IFN-β) minimal promoter fused to five copies of the NF-κB consensus transcriptional response element and three copies of the c-Rel binding site. These cells also express a secreted embryonic alkaline phosphatase (SEAP) reporter gene under the control of an IFN-stimulated gene 54 (ISG54) minimal promoter in conjunction with five IFN-stimulated response elements. As a result, Jurkat-Dual™ cells allow the simultaneous study of the NF-κB pathway, by monitoring the activity of Lucia luciferase, and the IRF pathway, by assessing the activity of SEAP. Both reporter proteins are readily measurable in the cell culture supernatant when using QUANTI-Luc™ 4 Lucia/Gaussia, a Lucia and Gaussia luciferase detection reagent, and QUANTI-Blue™ Solution, a SEAP detection reagent.

Jurkat-Dual™ cells induce the activation of NF-κB in response to TNF-α and T-Lymphocyte mitogens, such as phytohemagglutinin and concanavalin A. They trigger the IRF pathway upon stimulation with type I IFNs and poly(I:C).

Features of Jurkat-Dual™ cells:

  • Readily assessable SEAP and Lucia luciferase reporter activity
  • The stability for 20 passages has been verified
  • Functionally tested and guaranteed mycoplasma-free

Application of Jurkat-Dual™ cells:

  • Monitoring IRF and NF-κB activation in T lymphocytes


NF-κB and IRF responses of Jurkat-Dual™ Cells
NF-κB and IRF responses of Jurkat-Dual™ Cells

NF-κB/IRF dual response of Jurkat-Dual™ cells to various stimuli. Cells were incubated with 20 μg/ml of the mitogens phytohemagglutinin-P (PHA-P, the protein form of PHA) or concanavalin A (ConA), 300 IU/ml IFN-α, 300 IU/ml IFN-β, 100 ng/ml TNF-α or 10 μg/ml poly(I:C). After 24h incubation, NF-кB and IRF activation was assessed by measuring the levels of SEAP and Lucia luciferase in the supernatant using QUANTI-Luc™ or QUANTI‑Blue™ Solution, respectively.

Back to the top


Antibiotic resistance: Zeocin®blasticidin

Growth medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS; 30 min at 56 °C), 100 μg/ml  Pen-Strep (100 U/ml-100 μg/ml), Normocin™

Quality control:

  • Reporter activity has been validated using functional assays.
  • The stability for 20 passages following thawing has been verified.
  • These cells are guaranteed mycoplasma-free.


All of these products are covered by a Limited Use License (See Terms and Conditions).

Back to the top


Shipped on dry ice (Europe, USA, Canada and some areas in Asia)

Back to the top


The human Jurkat cell line was established from acute T cell leukemia. Jurkat cells have been extensively used in vitro to delineate the signaling pathways induced by the engagement of T-cell receptors and to study the expression of various chemokine receptors susceptible to viral entry, particularly HIV [1]. T cell activation results in the nuclear translocation of transcription factors, such as IRFs (interferon regulatory factors) and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) to induce the expression of target genes. Knowledge of their signaling cascades, ease of culture, and transfection make Jurkat cells a convenient tool to screen for T-cell activation, anti-viral or anti-cancer drugs.



1. Montano M. 2014. Model systems. Translational Biology in Medicine. 9-33.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty